{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:59:20Z","timestamp":1791194360492,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005468","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,4,18]],"date-time":"2015-04-18T00:00:00Z","timestamp":1429315200000}}],"reference-count":121,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005468.pub2","type":"journal-article","created":{"date-parts":[[2015,4,18]],"date-time":"2015-04-18T01:38:01Z","timestamp":1429321081000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["TNF-alpha inhibitors for ankylosing spondylitis"],"prefix":"10.1002","volume":"2015","author":[{"given":"Lara J","family":"Maxwell","sequence":"first","affiliation":[{"name":"Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital - General Campus; Centre for Practice-Changing Research (CPCR); 501 Smyth Road, Box 711 Ottawa ON Canada K1H 8L6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Zochling","sequence":"additional","affiliation":[{"name":"Menzies Research Institute; Private Bag 23 Hobart Tasmania Australia 7001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[{"name":"Caphri Research Institute; Department of Rheumatology; P Debeyelaan 25 PO Box 5800 6202 AZ Maastricht Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder A","family":"Singh","sequence":"additional","affiliation":[{"name":"Birmingham VA Medical Center; Department of Medicine; Faculty Office Tower 805B 510 20th Street South Birmingham AL USA 35294"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella MS","family":"Veras","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montreal; \u00c9cole de Readaptaci\u00f3n; Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Tanjong Ghogomu","sequence":"additional","affiliation":[{"name":"University of Ottawa; Bruy\u00e8re Research Institute; 43 Bruy\u00e8re St Annex E, room 302 Ottawa ON Canada K1N 5C8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Benkhalti Jandu","sequence":"additional","affiliation":[{"name":"University of Ottawa; Centre for Global Health, Institute of Population Health; 1 Stewart Street Ottawa ON Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa; Department of Medicine; Ottawa ON Canada K1H 8M5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A","family":"Wells","sequence":"additional","affiliation":[{"name":"University of Ottawa; Department of Epidemiology and Community Medicine; Room H1281 40 Ruskin Street Ottawa ON Canada K1Y 4W7"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,18]]},"reference":[{"key":"10.1002\/14651858.CD005468.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","article-title":"Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial","volume":"53","author":"Bao","year":"2014","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0002|cit2","first-page":"ii72","article-title":"A double blind placebo controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis","volume":"47","author":"Barkham","year":"2008","journal-title":"Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD005468.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1136\/ard.2009.121327","article-title":"Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis","volume":"69","author":"Barkham","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab, a double-blind placebo controlled multicenter trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0006|cit6","unstructured":"Braun J Burgos-Vargas R van der Horst-Bruinsma IE Freundlich B Vlahos B Koenig AS Assessment of clinical efficacy in a randomized, double-blind study of etanercept and sulphasalazine in patients with ankylosing spondylitis Arthritis and Rheumatism 2008 S415"},{"issue":"4","key":"10.1002\/14651858.CD005468.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3899\/jrheum.110885","article-title":"Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement","volume":"39","author":"Braun","year":"2012","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD005468.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0009|cit9","unstructured":"Sieper J Moots R Taylor A Sato R Singh A Roberson D Assessment of patient-reported outcomes from a randomized, double-blind study of etanercept and sulphasalazine in patients with ankylosing spondylitis Arthritis and Rheumatism 2008 S580"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD005468.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant Human Tumor Necrosis Factor Receptor (Etanercept) for Treating Ankylosing Spondylitis","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Davis J van der Heijde Braun J Dougados M Clegg DO Kivits A Effiacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis Annals of the Rheumatic Diseases 2008 346 52","DOI":"10.1136\/ard.2007.078139"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1136\/ard.2004.035105","article-title":"Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks","volume":"64","author":"Davis","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/ard.2010.139261","article-title":"Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: Results of a randomised double-blind placebo-controlled study (SPINE)","volume":"70","author":"Dougados","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD005468.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2011-200308","article-title":"Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0016|cit16","unstructured":"Giardina AR Ferrante A Ciccia F Impastato R Miceli M Principato A A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis Rheumatology International 10.1007\/s00296-009-1157-3"},{"issue":"Suppl II","key":"10.1002\/14651858.CD005468.pub2-BIB0017|cit17","first-page":"399","article-title":"Infliximab and etanercept are both effective and safe in patients with ankylosing spondylitis. A two-year randomised study","volume":"66","author":"Impastato","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1756-185X.2012.01734.x","article-title":"Adalimumab significantly reduces inflammation and serumDKK-1 level but increases fatty deposition in lumbar spine inactive ankylosing spondylitis","volume":"15","author":"Hu","year":"2012","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0020|cit20","unstructured":"Huang F MacPeek D Shunle C Li Z Gu J Wu D Etanercept is effective and well tolerated in Chinese patients with ankylosing spondylitis: 6-week placebo-controlled trial followed by 6-week open-label treatment Annals of the Rheumatic Diseases 2008 Suppl II: 521"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0021|cit21","first-page":"741\u20135","article-title":"A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis","volume":"49","author":"Huang","year":"2010","journal-title":"Zhonghua Nei Ke Za Zhi (Chinese Journal of Internal Medicine)"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD005468.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1136\/annrheumdis-2011-200308","article-title":"Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD005468.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD005468.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3899\/jrheum.091042","article-title":"A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis","volume":"37","author":"Inman","year":"2010","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD005468.pub2-BIB0026|cit26","first-page":"1213","article-title":"CANaDian evaluation of Low dosE infliximab in ankylosing spondylitis (CANDLE)","volume":"35","author":"Inman","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD005468.pub2-BIB0027|cit27","first-page":"1211","article-title":"CANaDian evaluation of Low dosE Infliximab in Ankylosing Spondylitis (CANDLE) - 12 week magnetic resonance imaging evaluation of spinal inflammation with the SPARCC MRI method","volume":"35","author":"Maksymowych","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD005468.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3899\/jrheum.091043","article-title":"Low-dose infliximab (3 mg\/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study","volume":"37","author":"Maksymowych","year":"2010","journal-title":"Journal of Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD005468.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1002\/art.23044","article-title":"Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis","volume":"56","author":"Lambert","year":"2007","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0030|cit30","unstructured":"Maksymowych W Rahman P Keystone E Wong R Inman R M03-606 Study Group Efficacy of adalimumab in active AS: Results from the Canadian AS study Arthritis and Rheumatism 2005 S217"},{"issue":"10","key":"10.1002\/14651858.CD005468.pub2-BIB0031|cit31","first-page":"2030","article-title":"Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis","volume":"35","author":"Maksymowych","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD005468.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/ard.2004.022582","article-title":"Infliximab in combination with methotrexate in active ankylosing spondylitis: A clinical and imaging study","volume":"64","author":"Marzo-Ortega","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD005468.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/ker083","article-title":"High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)","volume":"50","author":"Navarro-Sarabia","year":"2011","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.24001","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period","volume":"59","author":"Braun","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD005468.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/art.21790","article-title":"Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab - Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study","volume":"54","author":"Braun","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0036|cit36","unstructured":"Heldmann F Brandt J Braun J EASIC Study Group European ankylosing spondylitis infliximab cohort (EASIC): safety of longterm therapy with infliximab in patients with ankylosing spondylitis Annals of the Rheumatic Diseases 2008 Suppl II:386"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0037|cit37","unstructured":"Heldmann F Brandt J van der Horst-Bruinsma Landewe R Sieper J Burmester G European Ankylosing Spondylitis Infliximab Cohort (EASIC): Safety of longterm therapy in patients with ankylosing spondylitis Annals of the Rheumatic Diseases 2009 626"},{"issue":"2","key":"10.1002\/14651858.CD005468.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and Safety of Infliximab in Patients with Ankylosing Spondylitis. Results of a Randomized, Placebo-Controlled Trial (ASSERT)","volume":"52","author":"Heijde","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0040|cit39","doi-asserted-by":"crossref","unstructured":"van der Heijde D Han C Bala M Williamson P Han J Braun J Infliximab improves fatigue and pain in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial Arthritis and Rheumatism 2005 s35","DOI":"10.1002\/art.20852"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0039|cit40","unstructured":"van der Heijde D Han C Bala M Williamson P Han J Braun J Infliximab improves fatigue and pain in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT) Annals of the Rheumatic Diseases 2005 318 9"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Davis Jr JC Revicki D van der Heijde DMF Rentz AM Wong RL Kupper H Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study Arthritis Care and Research 2007 1050 7 10.1002\/art.22887","DOI":"10.1002\/art.22887"},{"issue":"7","key":"10.1002\/14651858.CD005468.pub2-BIB0042|cit42","first-page":"1346","article-title":"Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: Results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS)","volume":"35","author":"Revicki","year":"2008","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0043|cit43","unstructured":"van der Heijde D Dijkmans B Schiff M Kivitz A de Vlam K Wordsworth P Maintenance of reduction in disease activity and partial remission in patients with ankylosing spondylitis (AS) - 3 year results from the adalimumab (Humira) trial evaluating long-term efficacy and safety in AS (ATLAS) Arthritis and Rheumatism 2008 S579"},{"issue":"7","key":"10.1002\/14651858.CD005468.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis","volume":"54","author":"Heijde","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","article-title":"Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial","volume":"68","author":"Heijde","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD005468.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kem069","article-title":"Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly","volume":"46","author":"Braun","year":"2007","journal-title":"Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD005468.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"Heijde","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0048|cit48","unstructured":"Barkham N Keen HI Coates P O'Connor EMA Hensor AD Fraser LS A randomized controlled trial of infliximab shows clinical and MRI efficacy in HLA B27 positive very early ankylosing spondylitis Annals of the Rheumatic Diseases 2008 Suppl II:382"},{"issue":"1","key":"10.1002\/14651858.CD005468.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/art.23167","article-title":"Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment","volume":"58","author":"Breban","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0050|cit50","doi-asserted-by":"crossref","unstructured":"Haibel H Rudwaleit M Listing J Heldmann F Wong RL Kupper H Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two Arthritis and Rheumatism 2008 1981 91 10.1002\/art.23606","DOI":"10.1002\/art.23606"},{"issue":"9","key":"10.1002\/14651858.CD005468.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/rheumatology\/ken207","article-title":"Short-term effiacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation","volume":"47","author":"Li","year":"2008","journal-title":"Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD005468.pub2-BIB0052|cit52","first-page":"1138","article-title":"Direct imaging evidence that adalimumab induces resolution of inflammatory lesions in AS patients at sites of complete spinal ankylosis","volume":"38","author":"Morency","year":"2011","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.61.3.207","article-title":"Repeated infusions of infliximab, a chimeric anti-TNF alpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up","volume":"61","author":"Kruithof","year":"2002","journal-title":"Annals of Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD005468.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy","volume":"46","author":"Bosch","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"19","key":"10.1002\/14651858.CD005468.pub2-BIB0055|cit55","first-page":"1846","article-title":"Efficacy of etanercept in patients with ankylosing spondylitis: A double-blind, randomized, placebo controlled trial. [Chinese]","volume":"18","author":"Zhang","year":"2009","journal-title":"Chinese Journal of New Drugs"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1258\/jhsrp.2008.008020","article-title":"Multiparameter evidence synthesis in epidemiology and medical decision-making","volume":"13 Suppl 3","author":"Ades","year":"2008","journal-title":"Journal of Health Services Research Policy"},{"issue":"8","key":"10.1002\/14651858.CD005468.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing Spondylitis Assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0058|cit58","first-page":"933","article-title":"Abatacept in rheumatoid arthritis: a new branch on the biologics tree (editorial)","volume":"144","author":"Boers","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.60.4.353","article-title":"Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients","volume":"60","author":"Boonen","year":"2001","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/ard.60.11.1033","article-title":"Withdrawal from labour force due to work disability in patients with ankylosing spondylitis","volume":"60","author":"Boonen","year":"2001","journal-title":"Annals of Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD005468.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Statistics in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD005468.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD005468.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2003.016717","article-title":"Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis","volume":"63","author":"Brandt","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD005468.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","article-title":"Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis","volume":"38","author":"Braun","year":"1995","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Annals of Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD005468.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/art.21790","article-title":"Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab - Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study","volume":"54","author":"Braun","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD005468.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3899\/jrheum.110885","article-title":"Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement","volume":"39","author":"Braun","year":"2012","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1136\/annrheumdis-2011-200308","article-title":"Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD005468.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD005468.pub2-BIB0070|cit70","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0071|cit71","unstructured":"Callhoff J Sieper J WeiB A Zink A Listing J Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axials spondyloarthritis: a meta-analysis Annals of the Rheumatic Diseases 10.1136\/annrheumdis-2014-205322"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0072|cit72","unstructured":"Dr. Chris Cates Visual Rx3. Dr Chris Cates' EBM website www.nntonline.com 2008"},{"issue":"11","key":"10.1002\/14651858.CD005468.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004800","article-title":"Sulfasalazine for ankylosing spondylitis","author":"Chen","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"14","key":"10.1002\/14651858.CD005468.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/sim.3594","article-title":"Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation","volume":"28","author":"Cooper","year":"2009","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD005468.pub2-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002822","article-title":"Physiotherapy interventions for ankylosing spondylitis","author":"Dagfinrud","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0077|cit77","unstructured":"Dias S Welton NJ Sutton AJ Ades AE National Institute for Health and Clinical Excellence Decision Support Unit NICE DSU technical support document 1: introduction to evidence synthesis for decision making www.cc-arcc.ca\/common\/pages\/UserFile.aspx?fileId=282147"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0078|cit78","unstructured":"Dias S Welton NJ Sutton AJ Ades AE National Institute for Health and Clinical Excellence Decision Support Unit NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials www.nicedsu.org.uk\/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0079|cit79","unstructured":"Dias S Welton NJ Sutton AJ Caldwell DM Lu G Ades AE National Institute for Health and Clinical Excellence Decision Support Unit NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials www.nicedsu.org.uk\/TSD4%20Inconsistency.final.15April2014.pdf"},{"issue":"Suppl iii","key":"10.1002\/14651858.CD005468.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"iii40","DOI":"10.1136\/ard.61.suppl_3.iii40","article-title":"Conventional treatments for ankylosing spondylitis","volume":"61","author":"Dougados","year":"2002","journal-title":"Annals of Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD005468.pub2-BIB0081|cit81","first-page":"696","article-title":"Primary ankylosing spondylitis, psoriatic and enteropathic spondyloarthropathy: a controlled analysis","volume":"18","author":"Edmunds","year":"1991","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0082|cit82","unstructured":"McMaster University GRADEpro. [www.gradepro.org]"},{"issue":"Suppl","key":"10.1002\/14651858.CD005468.pub2-BIB0083|cit83","first-page":"S217","article-title":"Efficacy and safety of adalimumab in the treatment of active ankylosing spondylitis: Preliminary results of an open-label, 20-week trial","volume":"50","author":"Haibel","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/BOR.0b013e32833aaf93","article-title":"Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?","volume":"22","author":"Haibel","year":"2010","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0086|cit86","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005468.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"ii13","DOI":"10.1136\/ard.62.suppl_2.ii13","article-title":"Comparison of the efficacy of the tumour necrosis factor (alpha) blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis","volume":"62","author":"Hochberg","year":"2003","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0088|cit88","article-title":"The spondyloarthropathies","volume-title":"Cecil Medicine","author":"Inman","year":"2011"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"896","DOI":"10.7326\/0003-4819-136-12-200206180-00011","article-title":"Update on spondyloarthropathies","volume":"136","author":"Khan","year":"2002","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/rheumatology\/kep422","article-title":"Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register","volume":"49","author":"Lord","year":"2010","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0091|cit91","first-page":"959","article-title":"Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety","volume":"29","author":"Maksymowych","year":"2002","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0092|cit92","first-page":"1356","article-title":"Canadian Rheumatolgy Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis","volume":"30","author":"Maksymowych","year":"2003","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0093|cit93","unstructured":"Maksymowych W Rahman P Keystone E Wong R Inman R M03-606 Study Group Efficacy of adalimumab in active AS: Results from the Canadian AS study Arthritis and Rheumatism 2005 S217"},{"issue":"10","key":"10.1002\/14651858.CD005468.pub2-BIB0094|cit94","first-page":"2030","article-title":"Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis","volume":"35","author":"Maksymowych","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD005468.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3899\/jrheum.091043","article-title":"Low-dose infliximab (3 mg\/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study","volume":"37","author":"Maksymowych","year":"2010","journal-title":"Journal of Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD005468.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H","article-title":"Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study","volume":"44","author":"Marzo-Ortega","year":"2001","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD005468.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jbspin.2008.08.010","article-title":"Impact of the ankylosing spondylitis on the professional activity","volume":"76","author":"Montacer","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0098|cit98","unstructured":"National Institute for Health and Clinical Excellence Adalimumab, etanercept and infliximab for ankylosing spondylitis. NICE technology appraisal guidance 143 www.nice.org.uk\/TA143 (accessed January 2010)"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0099|cit99","unstructured":"National Institute for Health and Clinical Excellence Golimumab for the treatment of ankylosing spondylitis: NICE technology appraisal guidance 233 www.nice.org.uk\/guidance\/ta233\/resources\/guidance-golimumab-for-the-treatment-of-ankylosing-spondylitis-pdf 2011"},{"issue":"1","key":"10.1002\/14651858.CD005468.pub2-BIB0100|cit100","first-page":"80","article-title":"Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study","volume":"32","author":"Pavy","year":"2005","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0101|cit101","unstructured":"Huwaldt JA Steinhorst S Plot Digitizer"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0102|cit102","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to TNF- blockers in ankylosing spondylitis?","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ard.2009.108217","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schultz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0107|cit107","unstructured":"Sch\u00fcnemann H Bro\u017cek J Oxman A GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 The GRADE Working Group. updated March 2009"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0108|cit108","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"b1147","DOI":"10.1136\/bmj.b1147","article-title":"Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews","volume":"338","author":"Song","year":"2009","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0110|cit110","unstructured":"Spiegelhalter D Thomas A Best N Lunn D WinBUGS user manual [Internet]. Version 1.4 Cambridge, UK: MRC Biostatistics Unit, Institute of Public Health"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0111|cit111","first-page":"1605","article-title":"Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis","volume":"28","author":"Stone","year":"2001","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD005468.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1191\/1740774505cn072oa","article-title":"Prior distributions for the intracluster correlation coefficient, based on multiple previous estimates, and their application in cluster randomized trials","volume":"2","author":"Turner","year":"2005","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy","volume":"46","author":"Bosch","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0115|cit115","first-page":"2225","article-title":"Preliminary core sets for endpoints in ankylosing spondylitis","volume":"24","author":"Heijde","year":"1997","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD005468.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"Heijde","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD005468.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0118|cit118","unstructured":"Wells GA Sultan SA Chen L Khan M Coyle D Canadian Agency for Drugs and Technologies in Health Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis www.cadth.ca\/media\/pdf\/H0462_itc_tr_e.pdf 2009"},{"issue":"7","key":"10.1002\/14651858.CD005468.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/rheumatology\/ken190","article-title":"Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations","volume":"47","author":"Yazici","year":"2008","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD005468.pub2-BIB0120|cit120","first-page":"613","article-title":"Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database","volume":"27","author":"Zink","year":"2000","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD005468.pub2-BIB0121|cit121","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","author":"Zochling","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005468.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:01:49Z","timestamp":1759996909000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005468.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,4,18]]},"references-count":121,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005468.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,18]]}}}